ClinicaliQ Trial Snapshot
- A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients — Recruiting • Phase I • Cardiology / Cardiovascular • NCT04604782.
- What is being tested: Safety, tolerability, and pharmacokinetics of regadenoson (a vasodilator) administered as a single dose during cardiac magnetic resonance (CMR) stress testing in paediatric patients across three age groups starting from 12 years old.
- Patient eligibility overview: Paediatric patients aged 12 years and above who have a clinical indication for pharmacologic stress perfusion CMR testing are eligible; this is an open-label, multi-centre study design.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to
Eligibility Snapshot
- : * * Male or female adolescent aged from 12 to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.